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RESEARCH ARTICLE Open Access
The role of GAGE cancer/testis antigen in
metastasis: the jury is still out
Morten Frier Gjerstorff1*, Mikkel Green Terp1, Malene Bredahl Hansen1 and Henrik Jørn Ditzel1,2
Abstract
Background: GAGE cancer/testis antigens are frequently expressed in various types of malignancies and represent
attractive targets for immunotherapy, however their role in cancer initiation and progression has remained elusive.
GAGE proteins are expressed in normal cells during early development with migratory and invasive properties and
were found to be upregulated in cancer cells with metastasizing potential in a gastric cancer model.
Methods: We have addressed the direct role of GAGE proteins in supporting metastasis using an isogenic
metastasis model of human cancer, consisting of 4 isogenic cell lines, which are equally tumorigenic in
immunodeficient mice, but differ with their ability to generate metastases in the lungs and lymph nodes.
Results: Although GAGE proteins were strongly upregulated in the highly metastatic clone (CL16) compared to
non-metastatic (NM2C5), weakly metastatic (M4A4) and moderately metastatic clones (LM3), stable downregulation
of GAGE expression did not affect the ability of CL16 cells to establish primary tumors and form metastasis in the
lungs of immunodeficient mice.
Conclusions: These results suggest that GAGE proteins per se do not support metastasis and that further studies
are needed to clarify the contribution of GAGE proteins to the metastatic potential of different types of cancer cells.
Background
Metastasis is the cause of most cancer-related deaths
and remains the most significant challenge to manage-
ment of the disease. Thus it is essential to gain more
insight into the mechanisms of the metastatic process.
Several lines of evidence link the GAGE cancer/testis
antigen family to cancer metastasis. This is an highly
interesting observation since GAGE proteins have at-
tracted significant interest as potential targets for im-
munotherapy due to their near cancer-specific expression
and ability to elicit immune responses in patients [1]. Dur-
ing early human development, GAGE proteins are
expressed in the cells of the trophectoderm [2], which in-
vade the uterine tissue during blastocyst implantation, and
in primordial germ cells when they migrate from the yolk
sac to colonize the fetal testis [3]. Furthermore, knock-
down of GAGE proteins in melanoma cell lines has been
demonstrated to significantly reduce their ability to
migrate [4]. Thus, there is clearly a potential link between
GAGE proteins and a migratory and invasive phenotype
that deserves further investigation.
In a recent study Lee et al. reported on a metastasis
model of gastric cancer and identified a panel of genes
differentially expressed in primary tumors vs. corre-
sponding distant metastasis using mRNA microarray [5],
including members of the GAGE12 family. Based on fur-
ther experiments, the authors concluded that GAGE12
mediates human gastric carcinoma metastasis, but we
find no direct data presented to supports this. Knock-
down of GAGE12 expression in cancer cells derived
from metastasis was shown to reduce the ability of the
cells to form primary tumors when injected into the gas-
tric wall of immunodeficient mice, but the ability of the
cells to form metastasis at distant sites was not investi-
gated. The relationship between primary tumor size,
tumor cell dissemination and metastasis are compli-
cated. For instance, it has been shown that some tumors
disseminate metastasizing cells at an early stage and that
these cells remain dormant at ectopic sites and subse-
quently undergo somatic progression, inducing metastatic
growth. Thus, the size of the primary tumor cannot be
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regarded as a direct measure of metastasis development
[6–8] and the study by Lee et al. did not demonstrate a
causal role for GAGE12 in metastasis.
We have also been intrigued by whether GAGE proteins
play a role in tumor metastasis and have investigated this
in an isogenic breast cancer metastasis model.
Methods
Cell culture
All cell lines were culture in DMEM, supplemented with
10 % FBS (Invitrogen), penicillin (100 U/ml) and strepto-
mycin (100 mg/ml) and kept at low passage for no more
than 3 months. The identity of the cell lines was con-
firmed using the Cell ID System (Promega, Madison,
WI, USA).
Lentiviral packaging of shRNA plasmids
HEK293T cells were transfected with packaging plasmids
pMD2.g, pRSV-Rev and pMDL g/p RRE (kindly pro-
vided by Didier Trone through Addgene, Cambridge,
MA, USA) and shRNA plasmids targeting homologous
regions of all known GAGE family members (purchased
from Sigma Aldrich, Brondby, Denmark;) or control
plasmid pLKO1. Target sequences for shRNAs were:
GAGE-shRNA1 (TRCN0000137608), 5’- CCA AAT
CCA GAG GAG GTG AAA -3’; GAGE-shRNA2
(TRCN0000137973), 5’- AGT GTG AAG ATG GTC
CTG AT -3’; GAGE-shRNA3 (TRCN0000138463), 5’-
CTC CTG AAA TGA TTG GGC CTA C -3’; GAGE-
shRNA4 (TRCN0000136873), 5’- CAG TTC AGT GAT
GAA GTG GAA -3’; GAGE-shRNA5 (TRCN00001376
84), 5’- GAA CCA GCA ACA CCT GAA GAA -3’.
After 72 h, lentivirus-containing media was harvested
and stored at -80 degrees.
Lentiviral transductions
Cells were seeded at a density of 20,000 cells/cm2 and
the next day transduced in media with 5 μg/ml of poly-
brene. After 16 h media was changed and after another
48 h 0.2 μg/ml of puromycin was added to select stable
transfectants. Cells were used for experiments after two
passages in selective media.
Western blotting
Sub-confluent monolayers of cells were washed twice in
PBS, lysed in RIPA buffer for 30 min on ice and cleared
by centrifugation at 15.000 rpm for 10 min at 4 °C. Sam-
ples were resolved by 4–20 % SDS-PAGE and electro-
blotted onto a PVDF membrane. The membrane was
incubated in PBS, 0.1 % Tween-20, and 5 % non-fat dry
milk powder to block remaining protein binding sites,
and then incubated with anti-GAGE mAb M3 (1/5000)
[9] followed by horseradish peroxidase conjugated goat
anti-mouse IgG (1/100.000) (DakoCytomation Denmark
A/S, Glostrup, Denmark). All antibody incubations
and washing steps were carried out in PBS, 0.1 %
Tween-20 and 1 % non-fat dry milk powder. The immu-
noreactive bands were visualized with ECL Western Blot
kit (Amersham Biosciences, Hilleroed, Denmark).
Immunohistochemical analysis
Cultured cells for immunostaining were fixed in 4 %
formaldehyde for 24 h, prepared as cellblocks using
Shandon Cytoblock (Thermo Electron Corporation,
Pittsburg, PA, USA) and embedded in paraffin. Tissue
sections were cut, deparaffinized, treated with 1.5 % H202
in Tris-buffered saline (pH 7.5) for 10 min to block en-
dogenous peroxidase activity, rinsed in distilled H2O,
demasked for antigen retrieval and washed in TNT buffer
(0.1 M Tris, 0.15 M NaCl, 0.05 % Tween-20, pH 7.5).
Anti-GAGE (clone M3) [9] was diluted 1:100 in antibody
diluent (DAKO Cytomation, Glostrup, Denmark) and
added to sections for 1 h at room temperature. Sections
were washed with TNT and incubated with horseradish
peroxidase-conjugated Envision (DAKO Cytomation) for
30 min, followed by another wash with TNT. The final
reaction product was visualized by incubating with 3,3’-di-
aminobenzidine (DAB) + substrate-chromogen for 10 min,
followed by washing with H2O and counterstaining of
sections with Mayers hematoxylin before mounting in
AquaTex (Merck Inc., Whitehouse Station, NJ, USA).
Xenograft metastasis model
Evaluation of the effect of GAGE on the formation of
primary tumors and spontaneous metastasis was carried
out as described previously [10]. This study and its
protocols were approved by the Animal Experiments
Inspectorate (ID: 2014–15–0201–00128).
Results and discussion
We have addressed the metastatic potential of GAGE
proteins using an isogenic breast cancer metastasis
model, derived from the metastatic breast carcinoma cell
line MDA-MB-435 [11]. Interestingly, we found that the
highly metastatic clone [M4A4-LM3-4 CL16 (CL16)]
was highly enriched with GAGE-positive cells compared
to non-metastatic (NM2C5), weakly metastatic (M4A4)
and moderately metastatic clones [M4A4-LM3–2 (LM3)]
(Fig. 1a). NM2C5, M4A4 and LM3 all had less than 1 %
positive cell, similar to the original MDA-MB-431 cell
line, while all cells of the CL16 clone were positive.
NM2C5 and M4A4 are equally tumorigenic in immuno-
deficient mice, but only the latter produce metastases in
the lungs and lymph nodes. Although NM-2C5-derived
primary tumors disseminate single cells to the lungs, they
remain dormant and do not form metastases. The moder-
ately metastatic LM3 and highly metastatic CL16 cell lines
were raised by cyclically culturing and orthotopically re-
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inoculating the cells of successive generations of metasta-
ses [11]. To examine whether GAGE proteins were dir-
ectly implicated in the increased metastatic potential of
CL16, we knocked down GAGE expression in these cells
using stable lentiviral transductions with shRNA vectors
(Fig. 1b) and investigated changes in the ability to
metastasize. CL16 cells with shRNA-mediated knockdown
of all known GAGE members (GAGE-shRNA2 and
GAGE-shRNA5) and vector-only controls (pLKO1.1-1
and pLKO.1–2) were orthotopically transplanted into the
mammary fat pads of female CB17 SCID mice. Five weeks
later the primary tumors were surgically removed, having
reached a size of 1.2 cm and knock down of GAGE ex-
pression was confirmed by immunohistochemistry (Fig. 1c
and d). After another two weeks, the mice were sacrificed
and the lungs removed for analysis of the metastatic bur-
den. Tumor cells were identified in lung sections by stain-
ing of human vimentin, and the total size of tumors was
quantified relative to lung size (Fig. 1e). This analysis dem-
onstrated no significant difference in metastatic burden
between the GAGE knockdown and control groups. Thus,
GAGE proteins do not seem essential for the metastatic
capability of CL16 breast cancer cells. Because GAGE pro-
teins may have significantly diverse functions in different
cancer types, GAGE expression should be considered in
the context of the essential signaling pathways in the
respective cancer cells. Thus, it is possible that GAGE
proteins mediate metastasis in other experimental models.
Conclusions
Based on currently available data, it cannot be con-
cluded that GAGE proteins play a role in metastasis.
Tumor antigens with direct roles in cancer develop-
ment and progression are considered prime targets
for immunotherapy, and thus the function of GAGE
proteins in cancer cells should be further character-
ized. The gastric cancer metastasis model reported by
Lee et al. may provide the basis for future studies directly
addressing the involvement of GAGE proteins in the
metastatic process.
Fig. 1 Characterization of the effect of GAGE proteins on the metastatic potential of breast cancer cells. a Immunohistochemical staining of GAGE
proteins in MDA-MB-435-derived cell lines with different metastatic potential as described in Montel et al. [11] (anti-GAGE mAb, clone M4 [9];
DAB). b Western blot analysis of GAGE in CL16 cancer cells transduced with 5 different GAGE-specific lentiviral shRNA vectors (GAGE-shRNA1–5),
empty vector (pLKO.1-1 and pLKO.1–2) or untransduced (CL16). c-d GAGE expression (C) and size (D) of primary tumors from CB17 mice implanted
with 106 GAGE-shRNA or pLKO.1-transduced CL16 cells and Matrigel (Sigma-Aldrich, St. Luis, Missouri, USA) into the mammary fat pat. e Quantification
of the metastasis burden in lungs of mice by staining of the excised and embedded lungs with an antibody specific to human vimentin and scoring
using NDP view software. Experimental groups were compared using the Students t-test (p values >0.05 was considered nonsignificant)
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